Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a research report issued on Thursday. Several other analysts have also commented on LXRX. Leerink Partnrs reiterated an “outperform” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, April 30th. Needham & Company LLC reissued a “hold” […]
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Leerink Partnrs in a note issued to investors on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, […]
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Lexicon Pharmaceuticals in a research report issued on Tuesday, April 30th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical company will post earnings per share of ($0.13) for the quarter. […]
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 7 2% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 14,460,000 shares, a growth of 38.0% from the June 15th total of 10,480,000 shares. Based on an average daily volume of 2,360,000 shares, the days-to-cover ratio […]